Article
Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.
Cell reports. Medicine - 17 Mar 2026
Le Bac Viet, Vekariya Umeshkumar, Toma Monika M, Nieborowska-Skorska Margaret, Caron Marie-Christine, Gozdecka Malgorzata, Haydar Zayd, Walsh Martin, Ghosh Jayashri, Vaughan-Williams Elaine, Podszywalow-Bartnicka Paulina, Kukuyan Anna-Mariya, Ziolkowska Sylwia, Atkins Jessica, Hadzijusufovic Emir, Chandramouly Gurushankar, Nejati Reza, Piwocka Katarzyna, Pomerantz Richard, Vassiliou George S, Huntly Brian J P, Valent Peter, Wasik Mariusz, Bellacosa Alfonso, Masson Jean-Yves, Gupta Gaorav P, Challen Grant A, Skorski Tomasz
Abstract excerpt
Myeloid malignancies carrying somatic DNMT3A mutations (DNMT3Amut) are refractory to standard therapy. DNMT3Amut leukemia cells accumulate toxic DNA double-strand breaks (DSBs) and stalled replication forks, rendering them dependent on DNA damage response (DDR). We report here that DNA polymerase theta (Polθ), a key element in DSB repair by end-joining (Polθ-mediated end-joining [TMEJ]) and in fork restarting,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
